Poly(ethylene glycol)-block-poly(d,l-lactic acid) micelles containing oligo(lactic acid)-paclitaxel prodrug: In Vivo conversion and antitumor efficacy.

Poly(ethylene glycol)-block-poly(d,l-lactic acid) (PEG-b-PLA) micelles affect drug solubilization, and a paclitaxel (PTX) loaded-PEG-b-PLA micelle (PTX-PM) is approved for cancer treatment due to injection safety and dose escalation (Genexol-PM®) compared to Taxol®. However, PTX-PM is unstable in blood, has rapid clearance, and causes dose-limiting toxicity. We have synthesized a prodrug for PTX (7-OH), using oligo(lactic acid) as a novel pro-moiety (o(LA)-PTX) specifically for PEG-b-PLA micelles, gaining higher loading and slower release of o(LA)-PTX over PTX. Notably, o(LA)-PTX prodrug converts into PTX by a backbiting reaction in vitro, without requiring esterases. We hypothesize that o(LA)-PTX-loaded PEG-b-PLA micelles (o(LA)-PTX-PM) has a lower C and higher plasma AUC than PTX-PM for improved therapeutic effectiveness. In Sprague-Dawley rats at 10 mg/kg, compared to o(LA)-PTX-PM (10% w/w loading) and PTX-PM (10%), o(LA)-PTX-PM (50% w/w loading) produces a 2- and 3-fold higher plasma AUC of PTX, lactic acid-PTX, and o(LA)-PTX (o(LA)-PTX), respectively. For o(LA)-PTX-PM at 10 and 50% w/w loading, PTX and lactic acid-PTX are major bioactive metabolites, respectively. Fast prodrug conversion of o(LA)-PTX in vivo versus in vitro (by backbiting) suggests that o(LA) is a good substrate for esterases. At 60 mg/kg (qwx3), o(LA)-PTX-PM (50%) has higher antitumor activity than o(LA)-PTX-PM (10%) and PTX-PM (10%) in a syngeneic 4T1-luc breast tumor model based on measurements of tumor volume, 4T1-luc breast tumor bioluminescence, and survival. Importantly, intravenous administration of o(LA)-PTX-PM is well tolerated by BALB/c mice. In summary, oligo(lactic acid)-PTX is more compatible than PTX with PEG-b-PLA micelles, more stable, and may expand the role of PEG-b-PLA micelles from "solubilizer" into "nanocarrier" for PTX as a next-generation taxane for cancer.